Recently, Olympus announced a global distribution agreement with Yesight Medical. Olympus has obtained the exclusive distribution rights for Yesight Medical's disposable urology series products in the United States, Canada, and parts of Europe and the Asia-Pacific region. This marks Olympus’s second collaboration with a Chinese disposable endoscope company. Previously, Olympus partnered with Avanos Medical, securing disposable bronchoscopes, disposable rhinoscopes, and other disposable endoscopes in the respiratory system field. With this new collaboration with Yesight Medical, Olympus gains access to a disposable urology endoscope series along with related consumables. As disposable endoscopes rise in prominence, the endoscopy landscape has undergone tremendous change. Currently, only Ambu can compete with Chinese disposable endoscope companies in this field, while other foreign enterprises are no longer able to keep up (Boston Scientific has also sought partnerships with Chinese disposable endoscope companies). Therefore, as the leading name in endoscopy, Olympus must collaborate with Chinese companies to make significant progress in the disposable endoscope market.

Recently, the National Standardization Management Committee announced the second batch of national standard validation points. The list covers 20 strategic emerging industries and key areas related to people's livelihood, including medical devices, artificial intelligence, green and low-carbon fields, with a total of 35 organizations selected nationwide in China. National standard validation points are important technical platforms aimed at improving the formulation, implementation, and supervision mechanisms of standards through scientific verification, technical evaluation, and standard optimization, enhancing the scientific nature, applicability, and advancement of national standards. With the support and organization of the Beijing Municipal Drug Administration and the Beijing Municipal Market Supervision Administration, the Beijing Institute of Medical Device Testing, as a unit recommended by the Beijing municipal government, has been approved as a national standard validation point in two directions: radiotherapy and nuclear medicine, and in vitro diagnostic reagents. This breakthrough fills the gap in standardization verification platforms for high-end medical equipment and technologies such as proton and heavy ion therapy, boron neutron capture therapy, radionuclide imaging diagnostics, molecular diagnostics, and gene sequencing in China, providing stronger technical support for the high-quality development of the medical device industry.

Recently, Jiuzhou Tong Medical Device Group Co., Ltd., a subsidiary of Jiuzhou Tong, and Chongqing Hongmao Long Enterprise Management Consulting Co., Ltd. jointly established Chongqing Jiuzhou Tong Herui Medical Technology Co., Ltd. The registered capital of Chongqing Jiuzhou Tong Herui Medical Technology Co., Ltd. is 15 million yuan, with Jiuzhou Tong Medical Device Group Co., Ltd. contributing 7.65 million yuan, holding a 51% stake. Its business scope includes the operation of Class III medical devices; leasing of Class III medical equipment; food sales; medical services, etc. This marks a new layout by Jiuzhou Tong in the medical device field. In 2024, Jiuzhou Tong's medical device sector achieved sales revenue of 33.887 billion yuan, accounting for approximately 22.32% of total revenue. Businesses such as OTC, medical, services, and OEM are developing simultaneously. In terms of medical business, Jiuzhou Tong Medical Device Group focuses on professional tracks including major surgery, vascular intervention, orthopedics, IVD, nursing consumables, medical equipment, and other high-value consumables, collaborating with over 60% of the world's top 100 multinational enterprises and over 80% of China’s top 100 industrial enterprises.

On September 5-6, 2025, the 3rd Global Surgical Robotics Conference was held at the Zhongguan Village Exhibition Center in Beijing, with over 600 professional guests in attendance. Rosenbott, a standout enterprise in orthopedic surgical robotics, was invited to participate. Dr. Wang Yu, Chairman and CEO, attended and delivered a keynote speech titled "Interdisciplinary Collaboration Between Medicine and Engineering Drives Surgical Robot Innovation." He shared Rosenbott's journey from aligning with clinical needs to becoming a "super assistant" for doctors, and introduced a series of original innovative products developed by the company. Subsequently, the "2025 Global Surgical Robotics Awards" were announced, where Rosenbott won the "Surgical Robotics Technology Innovation Award" for its breakthrough innovations in key technologies, and Dr. Wang Yu received the "2025 Surgical Robotics Entrepreneur of the Year Award." Rosenbott expressed gratitude for the support from all parties and pledged to continue focusing on the field of intelligent orthopedic surgical robotics, promoting the implementation and application of related solutions.

Nanjing Shanhai Medical Technology Co., Ltd.'s self-developed "Functional Neurosurgical Electrophysiological Recording and Stimulation Device" (trade name: Mingtong) has been approved for marketing by the National Medical Products Administration, becoming the first brain-computer interface Class III medical device approved in China and the first domestically produced invasive deep brain electrophysiological recording and stimulation device. The core application of this device is in deep brain stimulation surgery, with technical highlights including high-precision signal acquisition, real-time neural navigation, and multi-mode stimulation control, successfully breaking foreign technological monopolies and filling domestic gaps. The approval of "Mingtong" verifies the safety and effectiveness of domestically produced invasive brain-computer interface devices, providing a technical paradigm and clinical validation platform for subsequent BCI medical device research and development. As a national high-tech enterprise, this approval represents an important milestone in Shanhai Medical's R&D journey, with future plans to expand the clinical applications of BCI technology into more fields.

Recently, the "J-VALVE® TF Transcatheter Aortic Valve System," independently developed by Jiecheng Medical, a subsidiary of Gensight Medical, has been approved for innovative product registration by the NMPA. This system targets aortic regurgitation (AR), a common valvular disease, effectively addressing the dilemma faced by elderly, critically ill AR patients who previously had no access to minimally invasive devices. It marks a milestone in China’s interventional treatment devices for structural heart diseases. For a long time, AR patients have had limited treatment options due to high surgical risks and a global lack of targeted interventional devices. The advent of J-VALVE® TF represents a "from zero to one" breakthrough in China’s interventional treatment of aortic valve diseases, establishing the first dual-indication treatment pathway for both "stenosis and insufficiency," offering more comprehensive interventional treatment options for complex valvular disease patients and providing greater scope for precision medicine.

Recently, the State Council Information Office held a series of themed press conferences on "High-Quality Completion of the '14th Five-Year Plan'". Relevant officials from the National Health Commission introduced the development achievements of health work during the "14th Five-Year Plan" period. Lei Haichao, director of the National Health Commission, stated that during the "14th Five-Year Plan" period, the capacity, accessibility, and equity of health services in China have been continuously improved. In particular, the health standards valued by the general public have also seen continuous improvement. In terms of medical devices, the photon-counting CT independently developed in China has 2 to 3 times higher spatial resolution than traditional CT, faster scanning speed, significantly reduced radiation dose, and better efficiency and results. Chinese-produced orthopedic surgery robots and endoscopic soft tissue surgery robots have been successfully developed, greatly improving surgical precision and reducing trauma and pain for patients. Products such as Extracorporeal Membrane Oxygenation (ECMO), artificial hearts, and proton-heavy ion radiotherapy equipment have all achieved independent research and development and have been applied in clinical settings, allowing more patients to "access, afford, and benefit from" domestically produced high-end medical equipment.

Recently, the Shanghai Medical Products Administration launched the "Information Collection System for Innovative Medical Devices under Research." Through information-based methods, it aims to strengthen the investigation of innovative medical devices under development in Shanghai and enhance the efficacy of early-stage guidance. Scope of application: Class II or Class III medical devices with strong innovation and significant clinical value being developed by enterprises whose registered address is in Shanghai. Information collection is solely intended for the city's pharmaceutical regulatory system to gather details on innovative medical devices under research, enabling targeted early intervention and guidance. It does not serve as a basis for product applications in national or municipal innovative review procedures. The system’s main processes include enterprise reporting, receipt and assignment, follow-up investigation, feedback provision, and service guidance.

Recently, the "2025 Hainan Province Medical Device Industry Development Report (Preview Edition) Release Conference" was held in Haikou City. According to reports, the "2025 Hainan Province Medical Device Industry Development Report (Preview Edition)" was jointly released by the Hainan Nanhai Health Industry Research Institute and the MedPath International Medical Device Club. The report shows that since 2020, Hainan's medical device industry has achieved leapfrog development relying on the Free Trade Port policies. As of June this year, the number of medical device manufacturing enterprises in the province increased from 58 at the end of 2021 to 118, including eight Class III device manufacturers. The number of Class II device registration certificates has doubled annually over the past three years, reaching a total of 458, while the number of Class III device licenses quadrupled over the same period, totaling 27. In 2024, the industrial output value of Hainan Province’s medical device industry reached 6.71 billion yuan, with product structures advancing toward higher-end markets. High-tech products such as orthopedic implants and digital therapeutics continue to fill gaps in the market.

Recently, the People's Government of Guangdong Province released the "Audit Report on the Execution of the 2024 Provincial Budget and Other Fiscal Revenues and Expenditures." The report disclosed the audit results of drug and medical device procurement and bidding in public hospitals. According to the report, the audit covered the procurement of pharmaceuticals and medical devices by 16 public hospitals from 2022 to June 2024. Multiple issues related to drug and medical device procurement in public hospitals were identified. These involved medical equipment procurement amounting to 176 million yuan and medical consumables procurement totaling 95.9612 million yuan. Numerous hospitals were named for illegal procurement practices: six hospitals indirectly designated suppliers by improperly setting exclusive parameters, rendering the bidding process a mere formality, involving 13 medical equipment procurement projects worth 176 million yuan. Additionally, seven hospitals, after accepting free or low-cost medical equipment from consumables dealers, illegally bundled the procurement of reagents and consumables, amounting to 95.9612 million yuan.

Recently, the State Administration for Market Regulation approved the establishment of the National Medical Device In Vitro Diagnostics Industry Metrology and Testing Center. Currently, China's medical device in vitro diagnostics industry faces metrological challenges such as a lack of metrological standards, difficulties in metrological testing of core components, insufficient metrological testing capabilities for high-end in vitro diagnostic equipment, and incomplete establishment of metrological methods and testing capabilities. There is an urgent need to provide "full traceability chain, full industry chain, full life cycle" metrology and testing services to support domestic substitution and enhance international competitiveness. The National Medical Device In Vitro Diagnostics Industry Metrology and Testing Center will focus on the localization and high-end development of in vitro diagnostic reagents and devices. Emphasizing key common technologies in the industry, it will utilize intelligent and digital advanced technologies. At the research, production, and application ends of the industry, the center plans to conduct 15 innovative metrological testing method studies, including the traceability of semi-quantitative serum index test results. It will also develop specialized metrological measurement equipment, such as rapid temperature detection systems for Polymerase Chain Reaction (PCR) analyzers, to address critical metrology and testing bottlenecks affecting the safety of raw material supply chains that constrain industrial development.

Recently, it was learned from the Guangzhou Municipal Commerce Bureau that the China International Medical Equipment Fair (CMEF), known as the global medical "barometer," will be held in Guangzhou at the Canton Fair Complex. This industry feast, themed "Health·Innovation·Sharing – Jointly Drawing a New Blueprint for Global Healthcare," will become a key window for the biotechnology industry in the Guangdong-Hong Kong-Macao Greater Bay Area to connect with international resources and unleash innovative momentum. The exhibition area of this CMEF is nearly 1.6 million square meters, with more than 3,000 companies from over 10 countries and regions around the world showcasing tens of thousands of products, and is expected to attract more than 120,000 professional visitors. The exhibition will form an international "exhibition matrix" through multiple specialized exhibitions and sub-brand collaborations, creating a comprehensive service platform for the global medical device industry; more than 60 professional conferences and forums will be held concurrently, forming a global medical event driven by both "exhibition and academia." A highlight of this CMEF is the addition of the "International Healthy Lifestyle Exhibition," which aligns closely with the "Healthy China 2030" strategy and the upgrading demand for residents' health consumption, also opening up new avenues for Guangzhou's health consumption market.